Global Psoriasis Drug Market
Source: Transparency Market Research, 2019
Global Psoriasis Drug Market, US$ 17 Billion and 6% Y-o-Y growth
Global Psoriasis Drug Market
Source: Transparency Market Research, 2019
Psoriasis and its Burden
Psoriasis represents a major health problem globally. It is a chronic, recurrent, painful, disfiguring and disabling disease for which there is no cure. It may cover large parts of the body with patches which may heal and then come back repeatedly throughout a person’s life, causing negative effects on the quality, social, mental and productive life of sufferers.
Individuals with psoriasis are at higher risk of developing a number of other serious, systemic and impactful clinical conditions, including cardiovascular diseases, diabetes, malignancies, mental disorders, COPD, hepatic disease, multiple sclerosis, renal and inflammatory bowel disease.
Psoriasis represents a global health problem, with a prevalence ranging between 1% and 3% in most countries. More than 100 million people globally suffer from psoriasis, with 9 million of them in the USA and 14 million in Europe. Due to demographic trends new cases of psoriasis are emerging annually at a fast rate.
The burden of psoriasis is comparable with that of other serious chronic illnesses, such as cancer and cardiovascular diseases. In the USA the annual direct care costs of psoriasis were estimated at $63.2 billion, medical comorbidities were estimated to contribute $36.4 billion, losses of productivity $35.4 billion, so that overall it accounts for approximately $112 billion.
Global Topical Psoriasis Drug Market
Source: Transparency Market Research, 2019
Unmet Needs and Market Opportunity
There is no cure for psoriasis and care aims to treat skin manifestations, mainly by means of topical drugs for mild and moderate cases, accounting for 70% to 80% of all, and systemic drugs for the remaining severe cases
Currently approved mainstream topical treatments are suboptimal in terms of safety and efficacy, causing low satisfaction and adherence rates. Safety issues and high cost also represent a concern for long term systemic drug use. Thus, there significant un-treatment and under-treatment and yet serious unmet needs to be covered.
The global psoriasis drug market will exhibit a significant growth in the near future and is expected to double in size to 2027, when it is forecasted reach $35.7 billion. The topical segment, is also expected to exhibit rapid growth and is forecast to also double in size between today and 2027, when it is expected to reach $3.5 billion globally.
The RD treatment market as $478 million in 2019, and projected it to reach $610 million by 2027, registering a CAGR of 4.1% from 2020 to 2027 (https://www.alliedmarketresearch.com/).The topical product segment captures over 70.0% of the market, due to its ease of application, wide availability, and high cost-efficiency. Topical corticosteroids, hydrophilic creams, and topical antibiotics are the most widely used products in this segment.
The CIPN market is expected to grow significantly currently valued at 1584 Million USD in 2020 and is expected to reach 2473 million USD by the end of 2026, growing at a CAGR of 6.5% during 2021-2026 (https://www.360marketupdates.com/). Leading therapies used include calcium channel Á2-delta ligands, antidepressants and opioids.
Therapeutic options for patients with CIPN are presently limited, and pharmacological treatment focuses primarily on reduction or relief of neuropathic pain. CIPN is usually acutely managed by dose reduction or discontinuation of causative chemotherapy, potentially compromising treatment outcome. Currently, there is no causative proven therapy for the prevention and treatment of CIPN.
With an estimated 32 million cancer survivors worldwide, it is increasingly important to address the potential long-lasting impacts of successful cancer treatments. Neurological side effects of chemotherapy, including chemotherapy-induced peripheral neuropathy (CIPN), often produce persistent symptoms affecting sensation and balance in cancer survivors. Despite successful cancer treatment and long-term survival prospects, survivors may be left with long-term functional disability and reduced quality of life.
The global DN market is forecasted at US$ 7120 million by 2026 registering a CAGR of 8.2% (https://www.fortunebusinessinsights.com/). This market is propelled by a high and increasing prevalence of diabetes globally. Increasing prevalence of diabetic neuropathy in developing economies is expected growth this market segment significantly in the future. Corticosteroids hold the dominant position in current treatment.
Psoriasis is a chronic, recurrent, noncommunicable, painful, disfiguring and disabling disease for which there is no cure and with great negative impact and multiple forms of burden. The majority of psoriatic patients, i.e. 80%, have localized disease of mild severity that can be adequately treated in the majority of cases with topical agents. Currently mainstream first-line topical treatments include corticosteroids, vitamin D analogs, and their combinations., whilst older agents such anthralin, tar, and salicylic acid are still used. Research supports continued reliance on corticosteroids as first-line therapy, but comparable efficacy has been shown for vitamin D analogs. However, current topical treatments are sub-optimal in terms of efficacy and safety and non-adherence rates reach up to 90% in some studies. A novel biotopical is thus needed to prevent unnecessary or delay early escalation to expensive systemic drugs.
Psoriasis prevalence is 1-3% in adults The global psoriasis drug market is expected to grow from USD 19.6 billion in 2019 to USD 35.7 billion in 2027, exhibiting a compound annual growth rate (CAGR) of 9.1%. Between 2019 and 2027 the topical segment will increase significantly and is forecasted to grow from 1.803 billion US$ to 3.458 billion US$ in the aforementioned period (www.transparencymarketresearch.com).
Strontium has multiple uses and applications and has already been used in approved products by EMA and FDA, and due its mechanism of action it has found use in several dermatologic conditions in systemic and topical form.[37, 48] Due to its pleiotropic effects on skin and its beneficial effects in a number of dermatology conditions associated with oxidative stress, it is postulated that NAC could be also beneficial in derma conditions.[49-53] NAC is considered to be a particularly antioxidant agent and may paly a signifcant role in anti-inflammatory responses and assist in epidermal proliferation, so that it might be useful as a treatment modality for dermatological conditions, through several mechanisms. The number of clinical trials currently running on NAC. [17] Recent clinical studies on topical formulations have shown potential benefits in the therapy of lamellar ichthyosis in children [40] [41], in atopic dermatitis ,[39], melasma[54], ulcers in patients with bullous morphea[55], irritant contact dermatitis [56], and acne.[38, 57]
Atopic dermatitis is the most common type of eczema. Atopic dermatitis prevalence as high as 20% in children and 1-3% in adults. Atopic dermatitis affects more than 200 million people worldwide and is highly variable in terms of onset, severity, progression over time and response to treatment. Th rise in incidence rate of atopic dermatitis across the globe and increase in awareness about various skin diseases are projected to drive the atopic dermatitis drugs market during in the future and demand for newer and technologically enhanced products rising globally. Atopic dermatitis patients are unsatisfied with current small molecule and other topical therapeutic products available for treatment. A large proportion of patients with untreated or suboptimal quality of life due to dermatological disorders demands novel therapeutic drugs to address unmet medical needs. A survey conducted by the National Eczema Association on atopic dermatitis treatment revealed that around 86% of patients are not satisfied with their current treatments. The global atopic dermatitis drugs market is projected to expand at the CAGR of 16.6% to reach value of US$ 21.2 billion by the end of 2027. Significant unmet needs in the treatment of the atopic dermatitis, large growing, and underserved specialty dermatology industry, increasing number of research and development activities in the dermatology biological products, strong pipeline of the products ready to be launched in coming years, increasing healthcare spending in the developing regions are some of the major factors expected to contribute to the growth of the atopic dermatitis drugs market during the forecast period.